These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1356363)

  • 41. L-dopa challenge and relapse in schizophrenia.
    Davidson M; Keefe RS; Mohs RC; Siever LJ; Losonczy MF; Horvath TB; Davis KL
    Am J Psychiatry; 1987 Jul; 144(7):934-8. PubMed ID: 2886063
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Report on an open investigation on bromperidol, a neuroleptic of the butyrophenone series].
    Fleischhauer J
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():30-7. PubMed ID: 35476
    [No Abstract]   [Full Text] [Related]  

  • 43. Adjunctive fluoxetine improves global function in chronic schizophrenia.
    Goldman MB; Janecek HM
    J Neuropsychiatry Clin Neurosci; 1990; 2(4):429-31. PubMed ID: 1983785
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Electroconvulsive therapy in neuroleptic-induced parkinsonism.
    Goswami U; Dutta S; Kuruvilla K; Papp E; Perenyi A
    Biol Psychiatry; 1989 Jul; 26(3):234-8. PubMed ID: 2568133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices.
    Peralta V; Cuesta MJ; Caro F; Martinez-Larrea A
    Acta Psychiatr Scand; 1994 Nov; 90(5):354-7. PubMed ID: 7872040
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Measurement of serum neuroleptic concentration by radioreceptor assay: concurrent assessment of clinical psychosis ratings.
    Rosenblatt JE; Pert CB; Colison J; van Kammen DP; Scott R; Bunney WE
    Commun Psychopharmacol; 1979; 3(3):153-8. PubMed ID: 498748
    [No Abstract]   [Full Text] [Related]  

  • 47. Symptomatology and electrodermal activity as predictors of neuroleptic response in young male schizophrenic inpatients.
    Lindström EM; Ohlund LS; Lindström LH; Ohman A
    Psychiatry Res; 1992 May; 42(2):145-58. PubMed ID: 1352902
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients.
    Smith RC
    Arch Gen Psychiatry; 1994 May; 51(5):427-9. PubMed ID: 7910013
    [No Abstract]   [Full Text] [Related]  

  • 49. Topiramate for refractory schizophrenia.
    Millson RC; Owen JA; Lorberg GW; Tackaberry L
    Am J Psychiatry; 2002 Apr; 159(4):675. PubMed ID: 11925318
    [No Abstract]   [Full Text] [Related]  

  • 50. Vulnerability to relapse in schizophrenia.
    Zubin J; Steinhauer SR; Condray R
    Br J Psychiatry Suppl; 1992 Oct; (18):13-8. PubMed ID: 1356362
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of buspirone in seven schizophrenic subjects.
    Brody D; Adler LA; Kim T; Angrist B; Rotrosen J
    J Clin Psychopharmacol; 1990 Feb; 10(1):68-9. PubMed ID: 1968473
    [No Abstract]   [Full Text] [Related]  

  • 52. Treatment programme and long-term outcome in chronic schizophrenia.
    Kane JM
    Acta Psychiatr Scand Suppl; 1990; 358():151-7. PubMed ID: 1978476
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A team approach to pharmacologic treatment of chronic schizophrenia.
    Keith SJ; Starr S; Matthews SM
    Hosp Community Psychiatry; 1984 Aug; 35(8):802-5. PubMed ID: 6148301
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Neuroleptics in the prevention of schizophrenic relapse. Report of a meeting (author's transl)].
    Hartmann W; Kind J; Meyer JE; Müller P; Steuber H
    Nervenarzt; 1979 Nov; 50(11):734-7. PubMed ID: 43954
    [No Abstract]   [Full Text] [Related]  

  • 55. Strategies for enhancing drug therapy of schizophrenia.
    Schooler NR; Levine J
    Am J Psychother; 1983 Oct; 37(4):521-32. PubMed ID: 6140869
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prodromal signs of schizophrenic relapse.
    Herz MI; Simon JC
    Am J Psychiatry; 1986 Jan; 143(1):115-6. PubMed ID: 2867689
    [No Abstract]   [Full Text] [Related]  

  • 57. Low-dose depot medication in schizophrenia.
    Burnett PL; Galletly CA; Moyle RJ; Clark CR
    Schizophr Bull; 1993; 19(1):155-64. PubMed ID: 8095736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Continuous versus intermittent neuroleptic therapy in schizophrenia.
    Jolley AG; Hirsch SR
    Drug Saf; 1993 May; 8(5):331-9. PubMed ID: 8099290
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment of resistant schizophrenia with valproate and neuroleptic drugs.
    Moriñigo A; Martin J; Gonzalez S; Mateo I
    Hillside J Clin Psychiatry; 1989; 11(2):199-207. PubMed ID: 2577309
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Important issues in the drug treatment of schizophrenia.
    Davis JM; Schaffer CB; Killian GA; Kinard C; Chan C
    Schizophr Bull; 1980; 6(1):70-87. PubMed ID: 6102795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.